1 Introduction to Research & Analysis Reports
1.1 Metabolic Disorders Drugs Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Metabolic Disorders Drugs Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Metabolic Disorders Drugs Overall Market Size
2.1 Global Metabolic Disorders Drugs Market Size: 2022 VS 2029
2.2 Global Metabolic Disorders Drugs Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Metabolic Disorders Drugs Sales: 2018-2029
3 Company Landscape
3.1 Top Metabolic Disorders Drugs Players in Global Market
3.2 Top Global Metabolic Disorders Drugs Companies Ranked by Revenue
3.3 Global Metabolic Disorders Drugs Revenue by Companies
3.4 Global Metabolic Disorders Drugs Sales by Companies
3.5 Global Metabolic Disorders Drugs Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Metabolic Disorders Drugs Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Metabolic Disorders Drugs Product Type
3.8 Tier 1, Tier 2 and Tier 3 Metabolic Disorders Drugs Players in Global Market
3.8.1 List of Global Tier 1 Metabolic Disorders Drugs Companies
3.8.2 List of Global Tier 2 and Tier 3 Metabolic Disorders Drugs Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Metabolic Disorders Drugs Market Size Markets, 2022 & 2029
4.1.2 Glycogen Metabolism Disease Drug
4.1.3 Lipid Metabolism Disease Drug
4.1.4 Amino Acid Metabolism Drug
4.1.5 Other
4.2 By Type – Global Metabolic Disorders Drugs Revenue & Forecasts
4.2.1 By Type – Global Metabolic Disorders Drugs Revenue, 2018-2023
4.2.2 By Type – Global Metabolic Disorders Drugs Revenue, 2024-2029
4.2.3 By Type – Global Metabolic Disorders Drugs Revenue Market Share, 2018-2029
4.3 By Type – Global Metabolic Disorders Drugs Sales & Forecasts
4.3.1 By Type – Global Metabolic Disorders Drugs Sales, 2018-2023
4.3.2 By Type – Global Metabolic Disorders Drugs Sales, 2024-2029
4.3.3 By Type – Global Metabolic Disorders Drugs Sales Market Share, 2018-2029
4.4 By Type – Global Metabolic Disorders Drugs Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Metabolic Disorders Drugs Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.2 By Application – Global Metabolic Disorders Drugs Revenue & Forecasts
5.2.1 By Application – Global Metabolic Disorders Drugs Revenue, 2018-2023
5.2.2 By Application – Global Metabolic Disorders Drugs Revenue, 2024-2029
5.2.3 By Application – Global Metabolic Disorders Drugs Revenue Market Share, 2018-2029
5.3 By Application – Global Metabolic Disorders Drugs Sales & Forecasts
5.3.1 By Application – Global Metabolic Disorders Drugs Sales, 2018-2023
5.3.2 By Application – Global Metabolic Disorders Drugs Sales, 2024-2029
5.3.3 By Application – Global Metabolic Disorders Drugs Sales Market Share, 2018-2029
5.4 By Application – Global Metabolic Disorders Drugs Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Metabolic Disorders Drugs Market Size, 2022 & 2029
6.2 By Region – Global Metabolic Disorders Drugs Revenue & Forecasts
6.2.1 By Region – Global Metabolic Disorders Drugs Revenue, 2018-2023
6.2.2 By Region – Global Metabolic Disorders Drugs Revenue, 2024-2029
6.2.3 By Region – Global Metabolic Disorders Drugs Revenue Market Share, 2018-2029
6.3 By Region – Global Metabolic Disorders Drugs Sales & Forecasts
6.3.1 By Region – Global Metabolic Disorders Drugs Sales, 2018-2023
6.3.2 By Region – Global Metabolic Disorders Drugs Sales, 2024-2029
6.3.3 By Region – Global Metabolic Disorders Drugs Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Metabolic Disorders Drugs Revenue, 2018-2029
6.4.2 By Country – North America Metabolic Disorders Drugs Sales, 2018-2029
6.4.3 US Metabolic Disorders Drugs Market Size, 2018-2029
6.4.4 Canada Metabolic Disorders Drugs Market Size, 2018-2029
6.4.5 Mexico Metabolic Disorders Drugs Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Metabolic Disorders Drugs Revenue, 2018-2029
6.5.2 By Country – Europe Metabolic Disorders Drugs Sales, 2018-2029
6.5.3 Germany Metabolic Disorders Drugs Market Size, 2018-2029
6.5.4 France Metabolic Disorders Drugs Market Size, 2018-2029
6.5.5 U.K. Metabolic Disorders Drugs Market Size, 2018-2029
6.5.6 Italy Metabolic Disorders Drugs Market Size, 2018-2029
6.5.7 Russia Metabolic Disorders Drugs Market Size, 2018-2029
6.5.8 Nordic Countries Metabolic Disorders Drugs Market Size, 2018-2029
6.5.9 Benelux Metabolic Disorders Drugs Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Metabolic Disorders Drugs Revenue, 2018-2029
6.6.2 By Region – Asia Metabolic Disorders Drugs Sales, 2018-2029
6.6.3 China Metabolic Disorders Drugs Market Size, 2018-2029
6.6.4 Japan Metabolic Disorders Drugs Market Size, 2018-2029
6.6.5 South Korea Metabolic Disorders Drugs Market Size, 2018-2029
6.6.6 Southeast Asia Metabolic Disorders Drugs Market Size, 2018-2029
6.6.7 India Metabolic Disorders Drugs Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Metabolic Disorders Drugs Revenue, 2018-2029
6.7.2 By Country – South America Metabolic Disorders Drugs Sales, 2018-2029
6.7.3 Brazil Metabolic Disorders Drugs Market Size, 2018-2029
6.7.4 Argentina Metabolic Disorders Drugs Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Metabolic Disorders Drugs Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Metabolic Disorders Drugs Sales, 2018-2029
6.8.3 Turkey Metabolic Disorders Drugs Market Size, 2018-2029
6.8.4 Israel Metabolic Disorders Drugs Market Size, 2018-2029
6.8.5 Saudi Arabia Metabolic Disorders Drugs Market Size, 2018-2029
6.8.6 UAE Metabolic Disorders Drugs Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Merck
7.1.1 Merck Company Summary
7.1.2 Merck Business Overview
7.1.3 Merck Metabolic Disorders Drugs Major Product Offerings
7.1.4 Merck Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.1.5 Merck Key News & Latest Developments
7.2 Novartis
7.2.1 Novartis Company Summary
7.2.2 Novartis Business Overview
7.2.3 Novartis Metabolic Disorders Drugs Major Product Offerings
7.2.4 Novartis Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.2.5 Novartis Key News & Latest Developments
7.3 Takeda Pharmaceutical
7.3.1 Takeda Pharmaceutical Company Summary
7.3.2 Takeda Pharmaceutical Business Overview
7.3.3 Takeda Pharmaceutical Metabolic Disorders Drugs Major Product Offerings
7.3.4 Takeda Pharmaceutical Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.3.5 Takeda Pharmaceutical Key News & Latest Developments
7.4 Astra Zeneca
7.4.1 Astra Zeneca Company Summary
7.4.2 Astra Zeneca Business Overview
7.4.3 Astra Zeneca Metabolic Disorders Drugs Major Product Offerings
7.4.4 Astra Zeneca Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.4.5 Astra Zeneca Key News & Latest Developments
7.5 Boehringer Ingelheim
7.5.1 Boehringer Ingelheim Company Summary
7.5.2 Boehringer Ingelheim Business Overview
7.5.3 Boehringer Ingelheim Metabolic Disorders Drugs Major Product Offerings
7.5.4 Boehringer Ingelheim Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.5.5 Boehringer Ingelheim Key News & Latest Developments
7.6 KOWA
7.6.1 KOWA Company Summary
7.6.2 KOWA Business Overview
7.6.3 KOWA Metabolic Disorders Drugs Major Product Offerings
7.6.4 KOWA Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.6.5 KOWA Key News & Latest Developments
7.7 Kythera
7.7.1 Kythera Company Summary
7.7.2 Kythera Business Overview
7.7.3 Kythera Metabolic Disorders Drugs Major Product Offerings
7.7.4 Kythera Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.7.5 Kythera Key News & Latest Developments
7.8 Fuji yakuhin
7.8.1 Fuji yakuhin Company Summary
7.8.2 Fuji yakuhin Business Overview
7.8.3 Fuji yakuhin Metabolic Disorders Drugs Major Product Offerings
7.8.4 Fuji yakuhin Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.8.5 Fuji yakuhin Key News & Latest Developments
7.9 LG Life Science
7.9.1 LG Life Science Company Summary
7.9.2 LG Life Science Business Overview
7.9.3 LG Life Science Metabolic Disorders Drugs Major Product Offerings
7.9.4 LG Life Science Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.9.5 LG Life Science Key News & Latest Developments
7.10 Metsubishi Tanabe Pharma
7.10.1 Metsubishi Tanabe Pharma Company Summary
7.10.2 Metsubishi Tanabe Pharma Business Overview
7.10.3 Metsubishi Tanabe Pharma Metabolic Disorders Drugs Major Product Offerings
7.10.4 Metsubishi Tanabe Pharma Metabolic Disorders Drugs Sales and Revenue in Global (2018-2023)
7.10.5 Metsubishi Tanabe Pharma Key News & Latest Developments
8 Global Metabolic Disorders Drugs Production Capacity, Analysis
8.1 Global Metabolic Disorders Drugs Production Capacity, 2018-2029
8.2 Metabolic Disorders Drugs Production Capacity of Key Manufacturers in Global Market
8.3 Global Metabolic Disorders Drugs Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Metabolic Disorders Drugs Supply Chain Analysis
10.1 Metabolic Disorders Drugs Industry Value Chain
10.2 Metabolic Disorders Drugs Upstream Market
10.3 Metabolic Disorders Drugs Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Metabolic Disorders Drugs Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer
世界の代謝障害治療薬市場予測2023-2029：グリコーゲン代謝疾患治療薬、脂質代謝疾患治療薬、アミノ酸代謝疾患治療薬、その他 |
| 【英語タイトル】Metabolic Disorders Drugs Market, Global Outlook and Forecast 2023-2029 | |
 | ・商品コード：MMG23JU5763 ・発行会社（調査会社）：Market Monitor Global ・発行日：2023年6月 ・ページ数：70 ・レポート言語：英語 ・レポート形式：PDF ・納品方法：Eメール（受注後2-3営業日） ・調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど ・産業分野：医薬品＆医療 |
| Single User（1名様閲覧用） | USD3,250 ⇒換算￥494,000 | 見積依頼/購入/質問フォーム |
| Multi User（20名様閲覧用） | USD4,225 ⇒換算￥642,200 | 見積依頼/購入/質問フォーム |
| Enterprise User（閲覧人数制限なし） | USD4,875 ⇒換算￥741,000 | 見積依頼/購入/質問フォーム |
|
※販売価格オプションの説明 ※お支払金額：換算金額（日本円）＋消費税 ※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡） ※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能） |
| 当調査レポートは次の情報を含め、世界の代謝障害治療薬市場規模と予測を収録しています。・世界の代謝障害治療薬市場：売上、2018年-2023年、2024年-2029年 ・世界の代謝障害治療薬市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界の代謝障害治療薬市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「グリコーゲン代謝疾患治療薬」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 代謝障害治療薬のグローバル主要企業は、Merck、 Novartis、 Takeda Pharmaceutical、 Astra Zeneca、 Boehringer Ingelheim、 KOWA、 Kythera、 Fuji yakuhin、 LG Life Science、 Metsubishi Tanabe Pharmaなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、代謝障害治療薬のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界の代謝障害治療薬市場：タイプ別、2018年-2023年、2024年-2029年 世界の代謝障害治療薬市場：タイプ別市場シェア、2022年 ・グリコーゲン代謝疾患治療薬、脂質代謝疾患治療薬、アミノ酸代謝疾患治療薬、その他 世界の代謝障害治療薬市場：用途別、2018年-2023年、2024年-2029年 世界の代謝障害治療薬市場：用途別市場シェア、2022年 ・病院、小売薬局 世界の代謝障害治療薬市場：地域・国別、2018年-2023年、2024年-2029年 世界の代謝障害治療薬市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業における代謝障害治療薬のグローバル売上、2018年-2023年 ・主要企業における代謝障害治療薬のグローバル売上シェア、2022年 ・主要企業における代謝障害治療薬のグローバル販売量、2018年-2023年 ・主要企業における代謝障害治療薬のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Merck、 Novartis、 Takeda Pharmaceutical、 Astra Zeneca、 Boehringer Ingelheim、 KOWA、 Kythera、 Fuji yakuhin、 LG Life Science、 Metsubishi Tanabe Pharma ************************************************************* ・調査・分析レポートの概要 代謝障害治療薬市場の定義 市場セグメント 世界の代謝障害治療薬市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界の代謝障害治療薬市場規模 世界の代謝障害治療薬市場規模：2022年 VS 2029年 世界の代謝障害治療薬市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでの代謝障害治療薬の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業の代謝障害治療薬製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：グリコーゲン代謝疾患治療薬、脂質代謝疾患治療薬、アミノ酸代謝疾患治療薬、その他 代謝障害治療薬のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、小売薬局 代謝障害治療薬の用途別グローバル売上・予測 ・地域別市場分析 地域別代謝障害治療薬市場規模 2022年と2029年 地域別代謝障害治療薬売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Merck、 Novartis、 Takeda Pharmaceutical、 Astra Zeneca、 Boehringer Ingelheim、 KOWA、 Kythera、 Fuji yakuhin、 LG Life Science、 Metsubishi Tanabe Pharma ... |
Metabolism Drugs is used to treat the metabolic disease in humans. Metabolic disease mainly covers Glycogen Metabolism Disease, Lipid Metabolism Disease, Amino Acid Metabolism, Metal Metabolism Disease, etc.
This report aims to provide a comprehensive presentation of the global market for Metabolic Disorders Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Metabolic Disorders Drugs. This report contains market size and forecasts of Metabolic Disorders Drugs in global, including the following market information:
Global Metabolic Disorders Drugs Market Revenue, 2018-2023, 2024-2029, ($ millions)
Global Metabolic Disorders Drugs Market Sales, 2018-2023, 2024-2029, (K Units)
Global top five Metabolic Disorders Drugs companies in 2022 (%)
The global Metabolic Disorders Drugs market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
Glycogen Metabolism Disease Drug Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Metabolic Disorders Drugs include Merck, Novartis, Takeda Pharmaceutical, Astra Zeneca, Boehringer Ingelheim, KOWA, Kythera, Fuji yakuhin and LG Life Science, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Metabolic Disorders Drugs manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Metabolic Disorders Drugs Market, by Type, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Metabolic Disorders Drugs Market Segment Percentages, by Type, 2022 (%)
Glycogen Metabolism Disease Drug
Lipid Metabolism Disease Drug
Amino Acid Metabolism Drug
Other
Global Metabolic Disorders Drugs Market, by Application, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Metabolic Disorders Drugs Market Segment Percentages, by Application, 2022 (%)
Hospital
Retail Pharmacy
Global Metabolic Disorders Drugs Market, By Region and Country, 2018-2023, 2024-2029 ($ Millions) & (K Units)
Global Metabolic Disorders Drugs Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Metabolic Disorders Drugs revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Metabolic Disorders Drugs revenues share in global market, 2022 (%)
Key companies Metabolic Disorders Drugs sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Metabolic Disorders Drugs sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck
Novartis
Takeda Pharmaceutical
Astra Zeneca
Boehringer Ingelheim
KOWA
Kythera
Fuji yakuhin
LG Life Science
Metsubishi Tanabe Pharma
Outline of Major Chapters:
Chapter 1: Introduces the definition of Metabolic Disorders Drugs, market overview.
Chapter 2: Global Metabolic Disorders Drugs market size in revenue and volume.
Chapter 3: Detailed analysis of Metabolic Disorders Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Metabolic Disorders Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Metabolic Disorders Drugs capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.
❖ レポートの目次 ❖
| ★調査レポート[世界の代謝障害治療薬市場予測2023-2029：グリコーゲン代謝疾患治療薬、脂質代謝疾患治療薬、アミノ酸代謝疾患治療薬、その他] (コード：MMG23JU5763)販売に関する免責事項を必ずご確認ください。 |
| ★調査レポート[世界の代謝障害治療薬市場予測2023-2029：グリコーゲン代謝疾患治療薬、脂質代謝疾患治療薬、アミノ酸代謝疾患治療薬、その他]についてメールでお問い合わせ |
